INTRODUCTION
Bacterial infection of the pulp results in necrosis. The inflammatory products of the necrosed pulp find their way to the periapical area, which leads to immune inflammatory response. Innate host response initially involves recognition of microbes and production of inflammatory mediators. Toll-like receptors (TLRs) expressed by resident cells and leucocytes activate innate immune response by binding to various bacterial components. [1] After TLR activation, an intracellular signalling cascade is initiated, that involves activation of transcription factors, resulting in the production of inflammatory cytokines, leukocyte, and osteoclast migration. [2] Bar Shavit demonstrated that the activation of TLRs in osteoblast induces production of osteogenic cytokines. [3] Among these cytokines, TNF-α, IL-1, and IL-6 are predominant. TNF-α leads to cell migration towards the infected and inflamed site, inducing the upregulation of adhesion molecules and production of chemotactic chemokines. [4, 5] It plays a central role in inflammatory reaction, bone resorption, and loss of connective tissue. It further upregulates the production of other proinflammatory innate immune cytokines such as IL-1β and IL-6. [4] [5] [6] The latter are involved in inflammatory cell migration and osteoclastogenic process. [6, 7] Absence of innate immunity cytokines attenuates inflammatory bone loss but their simultaneous inhibition results in more effective protection leading to almost complete remission of bone loss. [7, 8] The goal of endodontic treatment is the removal of necrotic, infected pulp tissue to inhibit inflammatory reaction in the periapical tissue, resulting in the formation of reparative bone. The latter could take 6 months or longer, and hence an earlier reversal of the resorptive process would lead to faster healing and resolution of the periapical lesion. In clinical trials, odanacatib (ODN) has been found to decreases bone resorption and increase bone density. It is currently being developed as an oral therapeutic agent for the treatment of osteoporosis and is undergoing phase 3 clinical trials. In the treatment of periapical diseases with ODN, the trabecular bone has been found to remain un-affected, whereas the inflammatory cell infiltration decreases. [9] Through a comprehensive literature review, this article aims to provide an overview of the role of ODN in reducing bone loss due to endodontic diseases.
MATERIALS AND METHODS

Search criteria
Inclusion criteria
The search was limited to research studies and review articles published between 2002 and 2016. Restrictions were not placed regarding the study design and the language used.
Exclusion criteria
Thesis, letters, and informative articles were excluded. Articles published prior to 2002 were also excluded.
Search strategy
A literature review was performed in PubMed Central, MEDLINE, Cochrane Library, and EBSCO host. The articles identified included those published between 2002 and 2016 with the following subject headings terms and/or keywords in various combinations: development and prevention of bone loss, periapical inflammation, cathepsin K, and odanacatib. Based on the predetermined inclusion and exclusion criteria, out of the 237 articles found, 50 were selected for this review [ Table 1 ].
DISCUSSION
Development of bone loss in periapical area
Bone loss and bone formation is an ongoing phenomenon throughout life. It occurs within discrete units called bone remodelling units (BMUs). Osteoclasts and osteoblasts are active at specific times within each BMU. Receptor Activator for Nuclear factor k B Ligand (RANKL) is produced by osteoblasts and is regulated by osteotropic hormones such as PTH and calcitriol, as well as cytokines such as IL6. RANKL plays an important role in osteoclast differentiation, activation, and survival. The binding of RANKL to its receptor, expressed in mononuclear hematopoietic precursors, initiates the process that ultimately leads to the formation of multinuclear osteoclast.
Pulpal necrosis arising from bacterial infection leads to periapical inflammation. The resultant periapical lesion displays infiltration of inflammatory cells, predominantly macrophages and T cells [10] in conjunction with the production of proinflammatory cytokines. [11, 12] Bone homeostasis is dependent upon the continuation of equilibrium between bone resorption by osteoclasts and bone formation by osteoblasts. Origin of osteoclast is from the hematopoietic precursors of monocyte, i.e., macrophage. They remain in the bone marrow and move from peripheral circulation into the bone on instructions of chemokines. Various chemokines such as MCP-1/CCL2, and SDF-1α/ CXCL12 tend to bring about osteoclast chemotaxis and differentiation, however, their activation is achieved only with RANKL. [13] The MIP-1α/CCL3 induces adhesion of osteoclast to primary osteoblasts. The MIP-1γ/CCL9 is dominant in the survival of osteoclast. RANKL effect plays a role in the survival of osteoclast depending on the ability to induce MIP-1γ/CCL9 production. [13] T cells by virtue of RANKL and IFN-γ production regulate osteoclastogenesis. [14] Surface of the activated T cells displays RANKL that activates bone resorbing cells. RANKL acts by binding to its Receptor Activator of Nuclear factor k B (RANK), which is a cell-surface protein. The latter is present on osteoclast precursor cells. On activation, it leads to osteoclast maturation. [15] RANK activates TNF receptor associated factor 6 (TRAF 6), c-Fos, and calcium signalling pathways, resulting in the induction and activation of NFATc1 (nuclear factor of activated T cells c1). The latter is the all-important factor for osteoclastogenesis. [14] In periapical granuloma, Vernal et al. established a direct relationship between high RANKL level and monocytes activity, leading to periapical bone destruction. [15] Osteoprotegerin (OPG) or osteoclastogenesis inhibitory factor (OICF) acts as the natural decoy receptor for RANKL. Balance between OPG and RANKL regulates osteoclast formation. [16] OPG by [1] 2016 In-vitro study TLR activates innate immune response. 2 Zhao et al. [4] 2016 In-vitro study TNF helps in the production of chemokines. 3 Khan et al. [13] 2016 In-vitro study MIP-1γ/CCL9 induces adhesion of ostooclast to primary osteoblast and helps in the survival of osteoclast. 4 Liu et al. [16] 2016 In-vivo study Equilibrium between OPG and RANKL governs osteoclast formation. Level of RANKL in periapical lesion is higher than healthy periapical tissue. 5 Hao et al. [9] 2015 In-vivo study ODN reduces bone resorption along with reduced number of inflammatory cells. ODN inhibits CtsK reducing bone loss through osteoclast inhibition, decreased activation, and differentiation. 6 Hao et al. [27] 2015 In-vivo study CtsK has important role in bone resorption and immune system. ODN can inhibit endodontic disease development, bone erosion, and immune response. 7 Gamsjager and Resch [30] 2015 In-vivo study CtsK inhibitors do not bind to bone for producing action. 8 Boggild [36] 2015 Review ODN does not reduce the number of osteoclast. 9 Wei et al. [37] 2015 In-vitro study ODN reduces bone resorption while preserving bone formation. 10 Chen et al. [2] 2014 In-vitro study TLR activation results in the production of cytokines and osteoclast migration. 11 Yang et al. [5] 2014 In-vivo study TNF helps in the production of chemokines. 12 Marton and Kiss [10] 2014 Review Periapical lesion has a predominance of macrophages and T cells. Bone loss is induced in periapical area due to infection from root apex. 13 Aranjo Piress et al. [11] 2014 In-vitro study Proinflammatory cytokines are produced in the periapical lesion. 14 Komatsu et al. [14] 2014 In-vivo study T cells govern osteoclastogenesis through production of RANKL and IFN-γ. Former is the master transcriptor for osteoclastogenesis. 15 Walsh and Choi [17] 2014 Review RANK/RANKL/OPG trio regulates bone remodelling and osteoclast activation. 16 Duong [24] 2013 Review CtsK plays an important role in bone resorption in periapical area. 17 Gao et al. [26] 2013 In-vivo study Ctsk has key role in bone resorption in inflammation mediated bone resorption diseases such as periapical diseases. Inhibition of CtsK inhibits bone resorption but osteoclast differentiation is affected only partially. 24 Schett [39] 2011 Review Cytokines are secreted from periapical inflammatory cells, which govern osteoclast, in turn controlling bone loss. 25 Eisman et al. [38] 2011 Eastell et al 2011 In-vivo study CtsK inhibitors have rapid onset and resolution for the anti resorptive effect. 29 Garlet [18] 2010 Review OPG reduces bone destruction (in periapical lesion) by stopping induction of RANKL.
Contd...
binding to the receptors on RANKL deny the latter the opportunity of binding with RANK, preventing RANKL-mediated osteoclast maturation. Bone remodelling is thus regulated by the RANK/RANKL/ OPG trio and is responsible for the development and activation of osteoclast. [17] Pro-inflammatory cytokines play a fundamental role in periapical bone destruction through induction of RANKL, whereas OPG synthesis attenuates lesion progression. [18, 19] Osteoclast by adhering to the surface of the bone, create "resorption lacuna." These result in resorption of bone. Towards the bone surface, they have ruffled border, delineated by clear zone. As the resorption lacuna becomes acidic, resorption is triggered. The acidic pH demineralizes the bone. Matrix proteins such as type I collagen are thus exposed and acted upon by enzymes such as cathepsin. The latter are cysteine proteinases, which become active in an acidic environment. [20, 21] RANKL directly induces osteoclast differentiation and activation, whereas its soluble decoy-receptor osteoprotegerin (OPG) neutralizes such osteoclastogenic effects. The level of RANKL mRNA expression in human periapical lesion is significantly higher than healthy periapical tissue, [15, 16] indicating that locally produced RANKL also leads to periapical bone resorption. The exact mechanism underlying increase of RANKL in the periapical lesion leading to bone resorption is unclear.
Cathepsin K
Cathepsin K (CtsK), the predominant cysteine protease is produced in osteoclast and plays an essential role 
Author
Year Study design
Finding/Summary 30 Black [34] 2010 Review Balicatib possess properties of lysosomotropism. 31 Isabel et al. [35] 2010 In-vitro study CtsK inhibitors are susceptible to interactions with other drugs due to metabolization by enzymes. 32 Sims [41] 2010 Review Release of growth factors from bone matrix is reduced with decreasing bone resorption, while communication between non-resorbing osteoclast and osteoblast is not affected. 33 Fonseca et al. [7] 2009 Review Inflammatory cytokines lead to osteoclastogenic process and their inhibition leads to remission of bone loss. 34 Podgorski [33] 2009 Review Relacatib interacts with paracetamol, ibuprofen and atorvastatin. It is metabolized by enzymes, such as cytochromes, making them susceptible for interaction with other drugs. 35 Bar-Shavit [3] 2008 Review Activation of TLR induces the production of osteogenic cytokines. 36 Graves [6] 2008 Review TNF regulates production of other proinflammatory cytokines, which are involved in inflammatory cell migration and osteoclastogenic process. 37 Menezes et al. [19] 2008 In-vitro study OPG restricts bone loss in periapical lesion by non-induction of RANKL. 38 Asagiri et al. [28] 2008 In-vitro study Cathepsin is required for expression of TLR in dendritic cell. It regulates microbial byproducts and activates defence response. CtsK regulates immune and inflammatory response. 39 Russell et al. [31] 2008 Review Concentration of CtsK within resorption lacunae is relevant for their activity. 40 Conchran [40] 2008 Review Proinflammatory cytokines and chemokines can inhibit CtsK. 41 Fujisaki et al. [23] 2007 In-vitro study Production of CtsK is upregulated by RANKL, TNF, and other agents, whereas it is downregulated by estrogen. 42 Chen et al. [29] 2007 In-vitro study CtsK deficiency leads to compromised bone resorption (as in osteopetrosis). 43 Kumar et al. [32] 2007 In-vivo study Relacatib has similar inhibitory potential for CtsK, L, and V, and selectively against CtsS and B. 44
Vernal et al. [15] 2006 In-vivo study RANKL acts by binding to RANK and promotes osteoclast maturation, leading to periapical bone destruction. 45 Zhao et al. [21] 2005 In-vivo study Cysteine proteinases under acidic conditions, within the resorption lacunae resorb bone. 46 Tolar et al. [20] 2004 Review Cysteine proteinases under acidic conditions, within the resorption lacunae resorb bone. 47
Vaaraniemi et al. [22] 2004 In-vitro study CtsK causes bone resorption by acting within the resorption lacunae. 48
Granes and Cochran [8] 2003
In-vitro study Inhibition of cytokines results in remission of bone loss. 49 Radics et al. [12] 2003 In-vivo study Proinflammatory cytokines are produced in periapical lesion. 50 Troen [25] 2002 Review CtsK plays an important role in bone resorption.
in osteoclast function and degradation of protein components of the bone matrix. In actively resorbing osteoclast, CtsK is localized at the ruffled border and discharged into the extracellular surface when the lysomal vesicles fuse with the cell membrane to degrade Type I and II collagen within the acidic microenvironment of resorption lacunae. [22] The production of CtsK is downregulated by estrogen and upregulated by RANKL and TNF among other agents capable of increasing osteoclast formation and differentiation, such as Vitamin D, PTH, and interleukins. [23] The inflammatory process magnifies in the apical area of the root canal and periapical region, resulting in periapical bone loss. [10] In this process, CtsK plays an important role. [24, 25] Inhibition of osteoclast-expressed enzyme CtsK reduces bone resorption due to pulpal infection. CtsK is crucial in normal bone remodelling, osteoporosis, osteoarthritis, and periapical diseases. [26] The role of CtsK in bone resorption has been confirmed in humans. It also plays an important role in the immune system. [27] Asagiri et al. found that cathepsin is essential in dendritic cells for expression of TLR 9, [28] which leads to the regulation of microbial products and activation of defence responses. [28] Inhibition of Cathepsin K CtsK deficiency in humans and mice leads to osteopetrosis (pycnodysostosia) with highly compromised bone resorption due to the inability to degrade the collagen matrix of bone. [29] Therefore, direct targeting of osteoclast may be the most effective strategy for inhibiting bone loss. The level of cytokines shows reduced levels in periapical tissue in CtsK treated animals. Asagiri et al. found Ctsk to regulate immune and inflammatory responses. [28] CtsK inhibitors have to be delivered into the lysosomes and they do not bind to bone for enforcing their activity. [30] Their activity is linked to their concentration in the resorption lacunae. [31] Inhibition of CtsK leads to diminished extracellular acidification and inhibits bone resorption; however, osteoclast differentiation is affected only partially. [26] For inhibition of CtsK various agents have been used. Relacatib was used earlier. It has equivalent inhibitory potential for CtsK, L, and V and partial for CtsS and B. [32] Its use was discontinued following drug interactions with paracetamol, ibuprofen, and atorvastatin. [33] Another selective inhibitor of Ctsk, possessing property of lysosomotropism, and balicatib, [34] was also tried but adverse dermatologic effects resulted in discontinuation as well. CtsK inhibitors are prone to drug interactions as a result of being metabolized by enzymes such as cytochrome CYP3A4. [33, 35] Odanacatib ODN is orally active, selective, effective, and reversible inhibitor of CtsK. It prevents bone resorption, arising out of the activity of osteoclast. It does not decrease the number of osteoclasts [36] rather decreases the magnitude of bone resorption and maintains the bone formation at the same time. [9, 37] It selectively inhibits proteolysis of matrix protein by CtsK, without affecting other osteoclast activities or viability, [38] with simultaneous inhibition of inflammation. This in turn decreases osteoclast activation and differentiation, which shows a promising therapeutic method on periapical inflammatory disease.
Periapical inflammatory cells secrete various cytokines (IL-1α, TNF-α, IL-6, IL-11), which activate apoptosis of osteoclast, thus controlling bone resorption. [39] Suppression of CtsK tends to affect immune response because pre-osteoclasts are activated by RANKL, produced by osteoblast, T, and B cells. The latter can be activated by proinflammatory cytokines and chemokines such as IL-1, IL-6, TNF-α, and IL-17. [40] In the periapical disease, innate immunity results in activated macrophages that through cytokines bring about bone resorption. Inhibition of CtsK impairs adaptive immune response by decreasing the number of T cells. Number of oestoblast also decreases, which results in lower proinflammatory cytokine production, leading to lower osteoclast activation and differentiation. [9] Growth factor release out of the bone matrix is diminished as a result of decreased bone resorption, whereas interaction between non-resorbing osteoclast and osteoblast may not be affected. [41, 42] The net effect of CtsK inhibition on bone formation could depend on off-setting the effects of the loss of growth factor release from bone matrix with the ongoing effect of coupling factors from the increased numbers of relatively healthy osteoclast. 
CONCLUSION
Infected pulp tissue leads to inflammatory reaction in the periapical tissue, resulting in bone resorption. Bone remodelling is controlled by the RANK/RANKL/OPG trio. The latter controls the genesis and activation of osteoclasts. Osteoclasts get attached to the bone surface, creating "resorption lacuna." Because the latter becomes acidic, resorption is triggered. Inhibition of osteoclast-expressed enzyme, cathepsin K, inhibits bone resorption. Odanacatib, a highly selective and potent inhibitor of CtsK, can be of help towards achieving this goal because of its ability to inhibit osteoclast-mediated bone resorption while preserving bone formation and other osteoclast activities or viability. Thus, the use of ODN can lead to faster resolution of bone resorptive process, as a result of pulpal and periapical disease.
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